Kancera AB (Sweden) Insiders

KAN Stock  SEK 1.02  0.08  7.27%   
Kancera AB employs about 5 people. The company is managed by 6 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 0.83 employees per reported executive. Breaking down Kancera AB's management performance can provide insight into the firm performance.
Thomas Olin  Insider
CEO Director
Martin Norin  Insider
Chief Officer
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kancera AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Kancera AB Management Team Effectiveness

The company has return on total asset (ROA) of (0.2736) % which means that it has lost $0.2736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4732) %, meaning that it generated substantial loss on money invested by shareholders. Kancera AB's management efficiency ratios could be used to measure how well Kancera AB manages its routine affairs as well as how well it operates its assets and liabilities.

Kancera AB Workforce Comparison

Kancera AB is currently regarded as number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 405. Kancera AB claims roughly 5.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.

Kancera AB Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Kancera AB Price Series Summation is a cross summation of Kancera AB price series and its benchmark/peer.

Kancera AB Notable Stakeholders

A Kancera AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kancera AB often face trade-offs trying to please all of them. Kancera AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kancera AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Kancera AB Management Performance

The success or failure of an entity such as Kancera AB often depends on how effective the management is. Kancera AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kancera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kancera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Please note, the imprecision that can be found in Kancera AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kancera AB. Check Kancera AB's Beneish M Score to see the likelihood of Kancera AB's management manipulating its earnings.

Kancera AB Workforce Analysis

Traditionally, organizations such as Kancera AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kancera AB within its industry.

Kancera AB Manpower Efficiency

Return on Kancera AB Manpower

Revenue Per Employee340.8K
Revenue Per Executive284K
Net Loss Per Employee9.1M
Net Loss Per Executive7.6M
Working Capital Per Employee2.2M
Working Capital Per Executive1.8M

Additional Tools for Kancera Stock Analysis

When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.